Literature DB >> 21538518

Long-term management issues in restless legs syndrome.

Sudhansu Chokroverty1.   

Abstract

Restless legs syndrome is a neurologic movement and sleep disorder with lifelong symptoms causing considerable morbidity. Several short-term and some long-term open-label and double-blind clinical trials have demonstrated the efficacy and safety of dopaminergic treatment in restless legs syndrome. Long-term treatment, however, is associated with the emergence of vexing long-term side effects that pose a challenge for physicians. These long-term complications can be broadly categorized as disease-related (impact on sleep and acute exacerbation of restless legs syndrome symptoms), and medication issues (augmentation, sleep attacks, impulse control disorders, addiction and dependence, site reaction, occasionally sleep apnea, fibrotic complications, and weight gain).
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 21538518     DOI: 10.1002/mds.23652

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  3 in total

1.  Increased Risk for New-Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large-Scale Retrospective Claims Matched-Cohort Analysis.

Authors:  Cheryl Hankin; Daniel Lee; Diego Garcia-Borreguero; Zhaohui Wang
Journal:  J Clin Sleep Med       Date:  2019-09-15       Impact factor: 4.062

Review 2.  Treatment of restless legs syndrome.

Authors:  Cynthia L Comella
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  The effects of long-term dopaminergic treatment on locomotor behavior in rats.

Authors:  Welinton Alessandro Oliveira de Almeida; Andrea Maculano Esteves; Canuto Leite de Almeida-Júnior; Kil Sun Lee; Miriam Kannebley Frank; Melise Oliveira Mariano; Roberto Frussa-Filho; Sergio Tufik; Marco Tulio de Mello
Journal:  Sleep Sci       Date:  2014-11-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.